Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR)

用于检测临床前糖尿病视网膜病变 (DR) 的动态示踪动力学模型

• 批准号: 10220617
• 负责人: JENNIFER J Kang-Mieler
• 金额: $ 53.08万
• 依托单位: ILLINOIS INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-01 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10220617
• 关键词: Address; Angiography; Angiotensin II Receptor; Angiotensin-Converting Enzyme Inhibitors; Animals; Biochemical; Biological Markers; Blindness; Blood Vessels; Blood flow; Cellular Structures; Centers for Disease Control and Prevention (U.S.); Characteristics; Clinical; Data; Detection; Diabetes Mellitus; Diabetic Retinopathy; Diagnostic; Diagnostic Imaging; Dose; Early Diagnosis; Early treatment; Evans blue stain; Fluorescein; Fluorescein Angiography; Genetic; Goals; Gold; Growth Factor Inhibition; Hyperglycemia; Imaging Device; Imaging technology; Intervention; Measurement; Measures; Methods; Microspheres; Modeling; Morphologic artifacts; Motion; Nature; Optical Coherence Tomography; Patients; Perfusion; Pericytes; Permeability; Phase; Protein Kinase C; ROC Curve; Receiver Operating Characteristics; Reporting; Retina; Retinal Diseases; Rodent Model; Scanning; Sensitivity and Specificity; Severities; Specificity; Structure; Surrogate Endpoint; Techniques; Technology; Testing; Time; Tracer; Translating; Vascular Endothelial Growth Factors; Vascular Permeabilities; Vascular remodeling; Vision; Visual impairment; Visualization; X-Ray Computed Tomography; adaptive optics scanning laser ophthalmoscopy; base; blood flow measurement; clinical examination; clinical practice; data acquisition; detection sensitivity; diabetic; diabetic patient; high risk; imaging modality; kinetic model; novel; novel therapeutics; polyol; pre-clinical; prevent; retina blood vessel structure; retinal damage; retinal imaging; statistics; success; tool; uptake

Project Summary Diabetic retinopathy (DR) is one of the most common complications associated with diabetes. Detection of clinical DR signs can take several years from the onset of diabetes; hence, the long preclinical phase should provide a window to apply interventions that can slow or prevent progression to clinical endpoint (mild to severe visual impairment). In fact, early detection and treatment of DR can prevent more than 90% of vision loss. However, the current unmet clinical challenge is finding an appropriate tool or technology to detect preclinical signs (biomarkers) of DR. Since the retinal vessels are early and prevalent targets of diabetic damage, sensitive identifiers of structural and functional blood vessel changes hold great potential as biomarkers. Recent advances in retinal imaging technology have allowed a better visualization of vessel characteristics. Adaptive Optics Scanning Laser Ophthalmoscopy (AOSLO) and OCT angiography (OCTA) studies recently suggested that there may be a transitional vascular remodeling during the preclinical phase in diabetic patients. Though the main benefit of these technologies is the non-invasive nature of data acquisition, there are limitations (e.g., long scan times, limited field-of-view, motion artifacts and need for an expert operator) that prevent these technologies to be effective preclinical detection tools to be used in a clinical setting. Therefore, there is a great need for enhanced detection sensitivity and quantitative means to analyze the early preclinical vasculature changes that can be readily translated into clinical practice. To address this critical unmet clinical need, we have developed a novel dynamic tracer kinetic model to measure quantitatively vascular permeability and blood flow changes based on fluorescein video-angiography (FVA). The approach is immediately translatable to FVA data collected in patients as demonstrated by our preliminary data. In this proposal, we will demonstrate that our dynamic tracer kinetic model can detect preclinical DR with a higher sensitivity and specificity than other retinal imaging modalities such as OCTA and AOSLO. Specific Aim 1 will optimize/validate the retinal vascular permeability and blood flow measurements against gold standard techniques of permeability (Evans-blue) and blood flow (microspheres). Specific Aim 2 will demonstrate that longitudinal preclinical changes in the retinal vascular permeability and blood flow detected by our model will occur before clinical retinopathy in diabetic rodent model. Specific Aim 3 will characterize longitudinal changes in retinal vascular permeability and blood flow in both normal subjects and diabetic patients. Specific Aim 4 will demonstrate higher sensitivity of preclinical DR detection by the dynamic tracer kinetic model over optical coherence tomography angiography (OCTA) and adaptive optics scanning laser ophthalmoscopy (AOSLO) in diabetic patients without clinical retinopathy (DMnoDR).

项目摘要 糖尿病视网膜病变(DR)是糖尿病最常见的并发症之一。检测 糖尿病的临床表现可能需要数年的时间；因此，较长的临床前阶段应该 提供一个应用干预措施的窗口，以减缓或防止进展至临床终点(轻微至 严重视力障碍)。事实上，早期发现和治疗DR可以阻止90%以上的视力 损失。然而，目前尚未满足的临床挑战是找到合适的工具或技术来检测 糖尿病的临床前体征(生物标记物)，因为视网膜血管是糖尿病的早期和流行的目标 损伤，结构和功能血管变化的敏感识别符具有巨大的潜力 生物标志物。视网膜成像技术的最新进展使血管有了更好的可视化 特点。自适应光学扫描激光眼底镜(AOSLO)和OCT血管造影(OCTA) 最近的研究表明，在临床前阶段可能存在过渡性血管重塑。 糖尿病患者。尽管这些技术的主要优点是数据采集的非侵入性， 存在一些限制(例如，较长的扫描时间、有限的视野、运动伪影和需要专家 操作员)阻止这些技术成为临床上使用的有效临床前检测工具 布景。因此，迫切需要提高检测灵敏度和定量分析手段 早期临床前血管改变，可以很容易地转化为临床实践。要解决这个问题 ，我们开发了一种新的动态示踪动力学模型来定量测量 血管通透性和血流量的变化基于荧光素视频血管造影(FVA)。方法是 如我们的初步数据所示，可立即转换为患者收集的FVA数据。在这 建议，我们将证明我们的动态示踪剂动力学模型可以检测到临床前DR具有更高的 与OCTA和AOSLO等其他视网膜成像方法相比，具有更高的敏感性和特异性。具体目标1将 对照金标准优化/验证视网膜血管通透性和血流量测量 渗透性(伊文思蓝)和血液流动(微球)技术。具体目标2将证明 我们的模型检测到的视网膜血管通透性和血流的临床前纵向变化将 糖尿病啮齿动物模型中视网膜病变发生在临床之前。具体目标3将描述纵向变化的特征 正常受试者和糖尿病患者的视网膜血管通透性和血流量。具体目标4将 通过动态示踪剂动力学模型比光学技术显示更高的临床前DR检测灵敏度 相干断层血管造影术(OCTA)和自适应光学扫描激光眼底镜(AOSLO) 糖尿病无临床视网膜病变患者(DMnoDR)。